Ohara, Kentaro
Rendeiro, André Figueiredo http://orcid.org/0000-0001-9362-5373
Bhinder, Bhavneet
Eng, Kenneth Wha
Ravichandran, Hiranmayi http://orcid.org/0000-0001-8671-7667
Nguyen, Duy
Pisapia, David
Vosoughi, Aram http://orcid.org/0000-0001-8833-5136
Fernandez, Evan
Shohdy, Kyrillus S.
Manohar, Jyothi
Beg, Shaham http://orcid.org/0000-0002-6068-1595
Wilkes, David http://orcid.org/0000-0002-2422-1145
Robinson, Brian D. http://orcid.org/0000-0001-5374-890X
Khani, Francesca http://orcid.org/0000-0001-7238-8604
Bareja, Rohan
Tagawa, Scott T. http://orcid.org/0000-0003-2777-8587
Ouseph, Madhu M.
Sboner, Andrea http://orcid.org/0000-0001-6915-3070
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Faltas, Bishoy M. http://orcid.org/0000-0002-6432-1693
Mosquera, Juan Miguel http://orcid.org/0000-0003-4666-6476
Article History
Received: 26 December 2021
Accepted: 22 February 2024
First Online: 18 March 2024
Competing interests
: B.M.F. Consulting or Advisory Role Astrin Biosceince, Inc, Natera, Guardant, Janssen, Boston Gene, Astra Biosciences, Gilead, Merck, Immunomedics, QED therapeutics and has received research support for Weill Cornell from Eli Lilly, received patent royalties from Immunomedics and Gilead Sciences and received honoraria from Urotoday. O.E. holds equity in OneThree Biotech, Volastra Therapeutics, Owkin, Champions Oncology, Pionyr Immunotherapeutics, Harmonic Discovery and Freenome. S.T.T. has received research funding (to Weill Cornell Medicine) from Sanofi, Astellas, Janssen, Amgen, Lilly, Genentech, BMS, AstraZeneca, Bayer, Merck, Abbvie, Clovis, Seagen, Novartis, Gilead, POINT Biopharma, Ambrx, and has received honoraria from Sanofi, Astellas, Janssen, Bayer, Eisai, Abbvie, Tolmar, Seagen, Amgen, Clovis, Pfizer, Novartis, Genomic Health, POINT Biopharma, Blue Earth, Aikido, Telix, Convergent, EMD Serono, Myovant, Merck, Daiichi Sankyo. The remaining authors declare no competing interests. No patents have been filed or are related to this manuscript.